Anti-RA33 Antibodies Are Present in Patients With Lyme Disease
This is the first study to identify anti-RA33 antibodies in patients with LA, though these antibodies did not identify a unique clinical subset of patients in this cohort. Unexpectedly, we found anti-RA33 antibodies at similar levels in patients with PTLD and EM RTH; further study is needed to determine the relevance of this finding.
Authors
- Laura C. Cappelli (ORCID: https://orcid.org/0000-0003-2795-7059)
- Erika Darrah (ORCID: https://orcid.org/0000-0003-1119-0279)
- John B. Miller (ORCID: https://orcid.org/0000-0002-8438-4413)
- John N. Aucott (ORCID: https://orcid.org/0000-0002-2648-0896)
- Alison W. Rebman (ORCID: https://orcid.org/0000-0001-7240-7158)
- Ting Yang (ORCID: https://orcid.org/0000-0002-2451-5864)
- Marcia Daniela Villegas de Flores
- Clifton O. Bingham (ORCID: https://orcid.org/0000-0002-4752-5029)
Institutions
- U.S. National Science Foundation (US)
- Apple (Israel) (IL)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
Publication Details
- Journal
- JCR Journal of Clinical Rheumatology
- Published
- 2024-11-22
- DOI
- https://doi.org/10.1097/rhu.0000000000002176
- Primary Topic
- Toxin Mechanisms and Immunotoxins
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Rheumatology Research Foundation
- Johns Hopkins University
- Jerome L. Greene Foundation
- National Institutes of Health